Thomas Crawford Marbury MD

Clinical Trials

• Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients Start of enrollment: 2005 Nov 01

  Completed

  Phase 2

• Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® Start of enrollment: 2007 Nov 01

  Completed

  Phase 1

• Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction Start of enrollment: 2007 Apr 30

  Terminated

  Phase 1, Phase 2

• Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects Start of enrollment: 2008 Dec 01

  Completed

  Phase 1

• The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil Start of enrollment: 2010 May 01

  Completed

  Phase 1

• A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function Start of enrollment: 2010 Oct 01

  Completed

  Phase 1

• A Study of Fostamatinib in Subjects With Impaired Kidney Function Start of enrollment: 2010 Nov 01

  Completed

  Phase 1

• Effect of Hepatic Impairment on LDK378 Pharmacokinetics Start of enrollment: 2014 Jan 01

  Completed

  Phase 1

• MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function Start of enrollment: 2014 Mar 01

  Terminated

  Phase 1

• To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects Start of enrollment: 2014 Mar 01

  Completed

  Phase 1

• To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects Start of enrollment: 2014 Mar 01

  Completed

  Phase 1

• A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects Start of enrollment: 2013 Oct 01

  Completed

  Phase 1

• Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Start of enrollment: 2014 Jul 01

  Completed

  Phase 2

• Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline Start of enrollment: 2014 Aug 01

  Completed

  Phase 1

• INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function Start of enrollment: 2015 Jun 12

  Completed

  Phase 1

• A Study of LY3113593 in Participants With Chronic Kidney Disease Start of enrollment: 2015 Nov 17

  Completed

  Phase 1

• Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment. Start of enrollment: 2015 Dec 21

  Completed

  Phase 1

• PK Study of T-817 in Subjects With Hepatic Impairment Start of enrollment: 2016 Feb 01

  Completed

  Phase 1

• The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate Start of enrollment: 2016 Oct 01

  Completed

  Phase 2

• Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants Start of enrollment: 2018 Mar 01

  Completed

  Phase 1

• A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants Start of enrollment: 2017 Jan 11

  Withdrawn

  Phase 1

• Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients Start of enrollment: 2017 Oct 01

  Completed

  Phase 1, Phase 2

• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function Start of enrollment: 2017 Dec 12

  Completed

  Phase 1

• A Phase 1 AVB-S6-500 Safety and Tolerability Study Start of enrollment: 2018 Jan 31

  Completed

  Phase 1

• Study of Danicopan in Participants With Hepatic Impairment Start of enrollment: 2018 May 01

  Completed

  Phase 1

• Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects Start of enrollment: 2022 Apr 25

  Completed

  Phase 1

  Roles: Contact

• Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days Start of enrollment: 2022 Mar 29

  COMPLETED

  PHASE3

  Roles: Contact

• Join now to see all